Abbott Laboratories (ABT)

Cash & Short-Term Investments

$5.60B

Quarterly · Period ending: · USD

ABT logo

ABT Cash & Short-Term Investments

Latest reported$5.60B
ABT Quarterly Cash & Short-Term Investments ($437.50M → $5.60B)
High-resolution chart · PNG

ABT cash & short-term investments history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Abbott Laboratories Cash & Short-Term Investments — Quarterly (USD)
Period endingCash & Short-Term Investments (USD)
5,603,000,000
7,295,000,000
8,939,000,000
7,733,000,000
7,282,000,000
6,844,000,000
7,967,000,000
7,788,000,000
7,219,000,000
6,651,000,000
7,279,000,000
7,047,000,000
8,155,000,000
9,532,000,000
10,170,000,000
9,907,000,000
9,290,000,000
8,158,000,000
10,249,000,000
9,692,000,000
8,944,000,000
8,372,000,000
7,148,000,000
4,731,000,000
5,037,000,000
3,668,000,000
4,140,000,000
4,335,000,000
3,376,000,000
3,261,000,000
4,086,000,000
7,550,000,000
3,264,000,000
4,042,000,000
9,610,000,000
11,199,000,000
9,835,000,000
8,860,000,000
18,775,000,000
4,507,000,000
4,438,000,000
3,957,000,000
6,125,000,000
6,139,000,000
11,177,000,000
9,849,000,000
4,460,000,000
4,877,000,000
7,062,000,000
7,047,000,000
8,098,000,000
8,605,484,000
9,393,592,000
8,517,313,000
15,173,984,000
11,504,522,000
11,002,138,000
9,526,561,000
8,097,359,000
7,976,502,000
8,893,499,000
8,375,839,000
5,451,450,000
3,849,951,000
4,372,778,000
1,822,073,000
9,932,048,000
8,695,152,000
6,887,943,000
5,703,777,000
5,079,625,000
3,766,470,000
5,178,274,000
3,636,599,000
2,820,827,000
2,548,950,000
2,237,074,000
1,641,879,000
1,373,435,000
1,051,134,000
1,096,840,000
2,404,662,000
2,956,093,000
2,927,658,000
1,534,702,000
1,814,519,000
2,058,962,000
1,911,293,000
2,423,347,000
2,053,867,000
1,286,421,000
1,753,351,000
1,173,788,000
1,289,022,000
966,127,000
1,013,860,000
703,146,000
993,879,000
713,540,000
790,944,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.